Journal of Labelled Compounds and Radiopharmaceuticals *J Label Compd Radiopharm* 2007; **50**: 471–472. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jlcr.1200

Short Research Article

Isotopic labelling with chlorine-37[†]

ALAN H WADSWORTH, STEVE MONTGOMERY, KENNETH W. M. LAWRIE* and RICHARD M. CARR

GlaxoSmithKline, Isotope Chemistry, Medicines Research Centre Gunnels Wood Road Stevenage SG1 2NY, UK

Received 18 August 2006; Revised 2 November 2006; Accepted 22 November 2006

Keywords: chlorine-37; mometasone furoate; sodium [³⁷Cl]chloride

Introduction

Mometasone furoate¹ is a potent corticosteroid marketed by Schering and a stable isotope labelled version 1 with eight extra atomic mass units (amu) was required as an internal standard. Mass labelling of mometasone furoate with only deuterium and carbon-13 would be a significant challenge without manipulation of the steroid skeleton. The use of chlorine-37 as an isotopic labelling tool is rarely considered, since the sole commercial source of chlorine-37 label is sodium [³⁷Cl]chloride, available with 95% incorporation. However, its use in a synthesis of **1** was considered feasible. leaving only four amu to be incorporated into the furoic acid moiety, a straightforward task. A chlorine-37 isotopic abundance of not less than 75% was needed for sufficient sensitivity of the mass spectrometric assay.

Results and discussion

Furoic acid **3** was prepared by lithiation of furan **2** with *n*-butyllithium, followed by quenching with [¹³C]carbon dioxide. The crude product was purified by sublimation to give furoic acid in 54% yield, and converted to the acid chloride in quantitative yield. In the published synthesis¹ of mometasone furoate,

hydroxyketone 5 is converted into unlabelled chloroketone 7 by reaction with tosyl chloride and triethylamine in dichloromethane. This occurs via formation of the intermediate tosylate 6, followed by subsequent displacement with in situ chloride ion. To incorporate a chlorine-37 label, this process requires separation of the two stages. Substitution of tosic anhydride for tosyl chloride allowed the clean conversion of alcohol 5 into tosylate 6. Reaction of **6** with sodium $[{}^{37}Cl]$ chloride (1.25 eq., ${}^{37}Cl/{}^{35}Cl =$ 95:5), partially solubilized in dimethylformamide with 18-crown-6, gave a quantitative yield of chloroketone 7. Conversion of 7 into 8 may potentially lead to dilution of the chlorine-37 labels with the unlabelled chlorine of furoyl chloride 4. However, in a trial labelled reaction at 80% conversion (20h) LC-MS showed a much greater dilution of the chlorine-37 label in unreacted 7 (${}^{37}Cl/{}^{35}Cl = 75:25$) compared to product 8 (92:8). After 4 days, these ratios had changed to 60:40 and 90:10 respectively, indicating that isotopic dilution was not a significant problem in the more sterically hindered environment of the tertiary furoyl ester 8.


Subsequently, a 60% molar excess of acylating agent **4** was found to give complete conversion to **8** in only 4 h with no significant dilution of the chlorine-37 label (92:8). The published method for the conversion of epoxide **8** into mometasone furoate requires a large excess of concentrated hydrochloric acid in chloroform. After much experimentation it was found that a mixture of sodium [³⁷Cl]chloride, concentrated sulphuric acid and a phase-transfer catalyst (tetrabutylammonium bisulphate) was an excellent alternative to concentrated hydrochloric acid. In this way, only four equivalents of sodium [³⁷Cl]chloride were required for



JLCR

^{*}Correspondence to: Kenneth W. M. Lawrie, GlaxoSmithkline, Isotope chemistry, Medicines Research centre Gunnels wood Road, Stevenage SG1 2NY, UK. E-mail: ken.w.lawrie@gsk.com

[†]Proceedings of the Ninth International Symposium on the Synthesis and Applications of Isotopically Labelled compounds, Edinburgh, 16–20 July 2006.



complete conversion of **8** into **1**. Isotopic dilution in the final product (**1**) was ${}^{37}\text{Cl}/{}^{35}\text{Cl} = 88:12$, but more importantly there was no unlabelled compound detected.

REFERENCE

1. Kwok DA, Tsai DJS, Tann C, Fu X. 1999. United States Patent 5886200, Schering.